News Image

NASDAQ:CORT is not too expensive for the growth it is showing.

By Mill Chart

Last update: Dec 5, 2023

Uncover the potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that our stock screener found to be reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. We'll examine each aspect in detail.

Assessing Growth Metrics for NASDAQ:CORT

ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:CORT scores a 7 out of 10:

  • CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.94% yearly.
  • CORT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.20%.
  • Measured over the past years, CORT shows a very strong growth in Revenue. The Revenue has been growing by 20.35% on average per year.
  • Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 22.09% on average per year.
  • Based on estimates for the next years, CORT will show a quite strong growth in Revenue. The Revenue will grow by 14.55% on average per year.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Valuation Analysis for NASDAQ:CORT

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:CORT has achieved a 5 out of 10:

  • Based on the Price/Earnings ratio, CORT is valued cheaper than 81.37% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 77.94% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 79.41% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, CORT is valued cheaply inside the industry as 84.80% of the companies are valued more expensively.
  • The excellent profitability rating of CORT may justify a higher PE ratio.
  • A more expensive valuation may be justified as CORT's earnings are expected to grow with 15.62% in the coming years.

A Closer Look at Health for NASDAQ:CORT

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:CORT has earned a 8 out of 10:

  • An Altman-Z score of 15.02 indicates that CORT is not in any danger for bankruptcy at the moment.
  • CORT has a better Altman-Z score (15.02) than 92.16% of its industry peers.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 3.54 indicates that CORT has no problem at all paying its short term obligations.
  • A Quick Ratio of 3.48 indicates that CORT has no problem at all paying its short term obligations.

Profitability Insights: NASDAQ:CORT

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:CORT has achieved a 8:

  • CORT's Return On Assets of 15.39% is amongst the best of the industry. CORT outperforms 95.10% of its industry peers.
  • CORT has a better Return On Equity (19.80%) than 91.67% of its industry peers.
  • CORT has a Return On Invested Capital of 18.44%. This is amongst the best in the industry. CORT outperforms 94.12% of its industry peers.
  • CORT had an Average Return On Invested Capital over the past 3 years of 23.51%. This is significantly above the industry average of 16.81%.
  • The last Return On Invested Capital (18.44%) for CORT is well below the 3 year average (23.51%), which needs to be investigated, but indicates that CORT had better years and this may not be a problem.
  • Looking at the Profit Margin, with a value of 20.31%, CORT belongs to the top of the industry, outperforming 94.61% of the companies in the same industry.
  • The Operating Margin of CORT (21.82%) is better than 89.71% of its industry peers.
  • With an excellent Gross Margin value of 98.64%, CORT belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of CORT

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/19/2024, 7:00:00 PM)

After market: 22.95 0 (0%)

22.95

+0.29 (+1.28%)

CORT News

News Imagea day ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

News Image5 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
News Image5 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image12 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
News Image19 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
News Image19 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image26 days ago - Market News VideoNotable Monday Option Activity: GME, LULU, CORT
News Image2 months ago - Seeking AlphaCorcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

CORT Links
Follow us for more